CAMBRIDGE, Mass. & BOTHELL, Wash.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (Nasdaq: SGEN), today reported data from a retrospective analysis of pediatric patients (12 – 17 yrs) enrolled in four multicenter clinical trials (two phase I and two phase II) of ADCETRIS. All patients were diagnosed with relapsed or refractory Hodgkin lymphoma (HL) (n=5) or systemic anaplastic large cell lymphoma (sALCL) (n=4) and had failed at least one prior chemotherapy regimen. The data were reported today during an oral presentation at the 2011 European Multidisciplinary Cancer Congress being held September 23 – 27, in Stockholm, Sweden.
